Immunoglobulin News and Research

RSS

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

An new study reports that a third dose of the Pfizer BNT162b2 vaccine produces high levels of anti-spike IgG antibodies in kidney transplant recipients.

6 Mar 2022

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Researchers develop an Omicron variant mRNA vaccine that is be more potent in generating nAbs as compared to other available vaccines.

6 Mar 2022

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

Researchers engineered a mutant ACE2 decoy that effectively protected human lung epithelia from SARS-CoV-2 infection by competitively binding to its spike protein.

3 Mar 2022

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Researchers assess the efficacy of 8G3, a B-cell neutralizing antibody against SARS-CoV-2 variants, including the most recent Omicron variant.

3 Mar 2022

Similarities between SARS-CoV-2 and human retroelements explored

A new study investigated the similarities between SARS-CoV-2 and human retroelements.

2 Mar 2022

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

The current study discusses a reliable ELISA that can detect three isotypes of antibody against three SARS-CoV-2 antigens.

2 Mar 2022

Effectiveness of Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing severe SARS-CoV-2 infection

A new study compared the effectiveness of the Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing SARS-CoV-2 infections.

1 Mar 2022

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

In a new study, researchers evaluated the immune responses induced by the mRNA-based SARS-CoV-2 vaccination against SARS-CoV-2 variants in multiple myeloma patients.

1 Mar 2022

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of three candidate vaccines, ED88, ED90, and ED94, to select the most appropriate one for future development.

1 Mar 2022

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Immunity before and after the SARS-CoV-2 Omicron variant in South Africa

Researchers conducted a national epidemiological survey to determine the seropositivity against SARS-CoV-2 before the emergence of the novel Omicron variant of concern.

28 Feb 2022

Health events amongst pregnant females after COVID-19 vaccination

Researchers evidenced that mRNA-based COVID-19 vaccines are safe in pregnancy, with lower rates of significant AEFIs in pregnant women than non-pregnant females.

28 Feb 2022

The epidemiology of COVID-19 in Africa

A new study uses the Africa CDC generic protocol for obtaining COVID-19 seroprevalence data to understand the spread and epidemiology of SARS-CoV-2.

27 Feb 2022

Outcomes of SARS-Cov-2 infection in patients undergoing active anti-cancer treatment

Researchers demonstrated that irrespective of the type of ACT, SARS-CoV-2 infection rates in patients receiving ACT remained comparable to the general population.

25 Feb 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Researchers assess the serological response to a real-world COVID-19 vaccination strategy in older individuals who resided in long-term care facilities.

24 Feb 2022

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

A recent study assessed the persistence of SARS-CoV-2 antibody five and 12 months post-infection in non-vaccinated patients.

24 Feb 2022

Edible egg-derived IgY antibodies against SARS-CoV-2 Omicron

A new study posted to the bioRxiv* preprint server reports on the development of anti-RBD immunoglobulin Y (IgY) antibodies from chicken eggs to block the binding of the viral RBD to human ACE2 receptors. This approach has several advantages since chicken egg-derived IgY can be edible and polyclonal can target multiple epitopes, enhancing neutralizing activity.

23 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

22 Feb 2022

Immunoglobulin News and Research

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Similarities between SARS-CoV-2 and human retroelements explored

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

Effectiveness of Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines in preventing severe SARS-CoV-2 infection

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Immunity before and after the SARS-CoV-2 Omicron variant in South Africa

Health events amongst pregnant females after COVID-19 vaccination

The epidemiology of COVID-19 in Africa

Outcomes of SARS-Cov-2 infection in patients undergoing active anti-cancer treatment

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

Edible egg-derived IgY antibodies against SARS-CoV-2 Omicron

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News